The world’s first cannabidiol (CBD) based drug approved by the U.S. Food and Drug Administration (FDA) has finally hit the markets. On November 1, 2018, GW Pharmaceuticals (NASDAQ: GWPH)  announced that its flagship drug, Epidiolex, is now available in all 50 U.S. states. The drug gained approval for medical use by the FDA earlier this summer, and in September the U.S. Drug Enforcement Administration classified it as a Schedule V drug. In order to help low-income patients afford the drug, which will reportedly cost patients around $32,500 a year without insurance, GW has launched a program called EPIDIOLEX Engage aimed at lowering out-of-pocket costs.